HC Wainwright Has Negative Outlook of PCSA FY2024 Earnings

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Processa Pharmaceuticals in a research note issued on Thursday, December 5th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($4.05) per share for the year, down from their previous estimate of ($3.78). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Processa Pharmaceuticals’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q4 2024 earnings at ($0.92) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.16) EPS.

Processa Pharmaceuticals Price Performance

Shares of PCSA opened at $1.25 on Monday. The firm has a market cap of $4.08 million, a PE ratio of -0.37 and a beta of 0.66. Processa Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $17.40. The stock’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $1.47.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.